Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis

T Graier, W Salmhofer, C Jonak, W Weger, C Kölli, B Gruber, P G Sator, K Prillinger, A Mlynek, M Schütz-Bergmayr, L Richter, G Ratzinger, C Painsi, S Selhofer, N Häring, K Wippel-Slupetzky, H Skvara, H Trattner, A Tanew, M InzingerR Tatarski, C Bangert, C Ellersdorfer, R Lichem, A Gruber-Wackernagel, A Hofer, F Legat, E Schmiedberger, R Strohal, B Lange-Asschenfeldt, M Schmuth, I Vujic, W Hoetzenecker, F Trautinger, W Saxinger, R Müllegger, F Quehenberger, P Wolf

Research output: Journal article (peer-reviewed) › Journal article

46 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science